ArticleLeukemia & lymphoma2022

Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL.

William G Wierda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.